Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Items 201–300 of 509
Natalicchio, A., Marrano, N., Montagnani, M., Gallo, M., Faggiano, A., Zatelli, M., Argentiero, A., Re, M. D., D’Oronzo, S., Fogli, S., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02417-z · Cited by 33
Sitagliptin for Type 2 diabetes: a 2015 update
Lee, M., & Rhee, M. K. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1046840 · Cited by 34
“] is inconsistent with the current data” [40].”
BackgroundResultDulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 29
Pharmacologic Treatment of Type 2 Diabetes: Injectable Medications
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 32
“Both agencies plan to continue to investigate the safety of these medications, and no changes to clinical practice have been recommended.(66,68,69) Package inserts for these agents continue to advise of pancreatitis and thyroid carcinoma risks, with a contraindication listed for exenatide extended-release, liraglutide…”
BackgroundTeneligliptin: Heralding Change in Type 2 Diabetes
Maladkar, M. N., Sankar, S., & Kamat, K. (2016) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2016.62012 · Cited by 36
“Casual association between incretin-based drugs and pancreatitis are inconsistent with current data [56], yet, it is advisable that Teneligliptin should not be used in patients with history of pancreatitis.”
BackgroundPace, D. J., Dukleska, K., Phillips, S. M., Gleason, V. M., & Yeo, C. J. (2018) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2018.0016 · Cited by 28
“Of importance, other oral hypoglycemics such as glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors have been associated with pancreatitis and heart failure, respectively.(7,8) Therefore, it is important for clinicians to be aware of these rare but important serious medication side effects.”
BackgroundAcute pancreatitis during GLP-1 receptor agonist treatment. A case report
Chis, B. A., & Fodor, D. (2018) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-804 · Cited by 26
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 29
“Concerns about a possible connection between GLP-1 RAs and the development of neoplasms have spurred several investigations, especially on thyroid and pancreatic cancers due to a plausible mechanism and a large number of reports in the post-marketing phase [118, 128, 130].”
Roshanov, P. S., & Dennis, B. B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.014 · Cited by 26
“Agency have issued warnings but no firm conclusion regarding the pancreatic safety of incretin-based oral antihyperglycemic agents, pending further evidence [1].”
BackgroundPerano, S., Rayner, C., Couper, J., Martin, J., & Horowitz, M. (2014) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2014.06.012 · Cited by 29
“Recent concerns relating to the potential association of incretin-based therapies with pancreatitis and pancreatic cancer have diminished (Egan et al., 2014) but need to be recognized, particularly in this patient group with pancreatic exocrine insufficiency.”
BackgroundSportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 27
DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty
Filion, K. B., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dci15-0036 · Cited by 27
“Nevertheless, concerns remain regarding their potential association with serious adverse effects including acute pancreatitis (3), pancreatic cancer (3), and heart failure (HF) (4).”
BackgroundSchludi, B., Moin, A. S. M., Montemurro, C., Gurlo, T., Matveyenko, A. V., Kirakossian, D., Dawson, D. W., Dry, S., Butler, P. C., & Butler, A. E. (2017) · JCI Insight · doi:10.1172/jci.insight.92282 · Cited by 29
“Of interest, administration of metformin suppressed and GLP-1–mimetic therapy amplified the increased proliferation in PDGs in the HIP rat model (22), consistent with some reports of decreased versus increased pancreatitis in patients with T2DM treated with these drugs (23, 24).”
ResultHyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 27
Gamble, J., Donnan, J. R., Chibrikov, E., Twells, L., Midodzi, W. K., & Majumdar, S. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-33483-y · Cited by 26
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
Goodarzi, M. O., & Petrov, M. S. (2023) · Drugs · doi:10.1007/s40265-023-01913-5 · Cited by 29
“As a result, any evidence-based benefit or harm of modern antidiabetic agents cannot be confidently extrapolated to DEP, despite reassurances from regulatory agencies [75].”
BackgroundDar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 26
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer
Amin, S., Boffetta, P., & Lucas, A. L. (2016) · Gut and Liver · doi:10.5009/gnl15451 · Cited by 25
“After exhaustive review of both preclinical and epidemiological studies, the authors conclude that current data do not support a causal relationship between DPP-4 inhibitors and either pancreatitis or pancreatic cancer.(34)”
BackgroundAlbiglutide: a unique GLP-1 receptor agonist
Rendell, M. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 23
“Their assessment of the totality of evidence, published in February 2014, was that there existed no causal association between use of GLP-1 RAs or DPP-4 inhibitors and possible pancreatitis and pancreatic cancer [61].”
BackgroundStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 33
“Reports of pancreatitis and pancreatic cancer with the use of incretinomimetics are still under investigation [37].”
BackgroundÅhrén, B., Carr, M. C., Murphy, K., Perkins, C., Rendell, M., Mallory, J. M., Wilson, T. H., & JOHNSON, S. L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.017 · Cited by 26
“Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stimulate the incretin system and lower glycaemic parameters in Type 2 diabetes mellitus (T2DM).”
BackgroundInfluentialA Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
Chikara, G., Sharma, P. K., Dwivedi, P., Charan, J., Ambwani, S. R., & Singh, S. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0668-z · Cited by 29
“Vildagliptin, Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin Nasopharyngitis, medullary thyroid cancer risk, concern for pancreatitis or pancreatic cancer [9]”
BackgroundDrug-induced diabetes type 2: In silico study involving class B GPCRs
Latek, D., Rutkowska, E. E., Niewieczerzał, S., & Cielecka‐Piontek, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208892 · Cited by 30
“Unfortunately, currently available agonists are peptides (GLP or GIP analogs) of low bioavailability and half-life [33] and potentially may increase other side effects themselves [31, 34].”
BackgroundSouto, M., Gonçalves, T. C., & Cotter, J. B. (2025) · Nutrients · doi:10.3390/nu17142310 · Cited by 26
“The current stance of the regulatory agencies EMA and FDA is that a causal link between incretin-based drugs and pancreatitis or PC has not been conclusively established [34].”
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
“Despite reassurances from both the FDA and the European Medicines Agency (33), the possible association between incretin therapy and acute pancreatitis and/or pancreatic cancer remains controversial.”
BackgroundManagement of Diabetes in Patients Undergoing Bariatric Surgery
Mulla, C. M., Baloch, H. M., & Hafida, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1242-2 · Cited by 27
Cancer stem cells as therapeutic targets of pancreatic cancer
Razi, E., Radak, M., Mahjoubin‐Tehran, M., Talebi, S., Shafiee, A., Hajighadimi, S., Moradizarmehri, S., Sharifi, H., Mousavi, N., Sarvizadeh, M., et al. (2019) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12521 · Cited by 24
Incretin based therapy and pancreatic cancer: Realising the reality
Suryadevara, V., Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2881 · Cited by 23
Chen, H., Zhou, X., Chen, T., Liu, B., Jin, W., Gu, H., Hong, T., & Zhang, G. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0198-3 · Cited by 24
“does not support a causal association between incretin-based drugs and pancreatic cancer [10],”
BackgroundExenatide extended-release: a once weekly treatment for patients with type 2 diabetes
Raskin, P., & Mann, K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35331 · Cited by 26
“The European Medicines Agency came to the same conclusion.(52,53) In a combined paper from both the US Food and Drug Agency and the European Medicines Agency, Egan et al(53) conducted a careful independent comprehensive review of all preclinical and human data of all incretin-based products (200 clinical trials involv…”
BackgroundBuysschaert, M., D’Hooge, D., & Preumont, V. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.05.001 · Cited by 25
Umpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Semaglutide for adults living with obesity
Bracchiglione, J., Meza, N., Franco, J. V. A., Liquitay, C. M. E., Victoria Novik, A., Vargas, M. O., Lazcano, G., Poloni, D., Langlotz, F. R., Figuls, M. R. I., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092.pub2 · Cited by 36
Tartaglia, E., Bucci, T., Rossi, M., Rigutini, A. G., Askarinejad, A., Alam, U., Nabrdalik, K., Boriani, G., & Lip, G. Y. H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02986-0 · Cited by 22
“Though not definitively established, this association is not unexpected: prescribing information for agents like liraglutide, exenatide, and dulaglutide has long included warnings or contraindications in people with prior pancreatitis or gallstone disease [24, 25].”
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 23
“However, post-market reas-sessment by the FDA and European Medicines Agency and large-scale meta-analyses of over 1 million patients have concluded that the current data do not support a link between incretin therapy and pancreatic side effects [157-159].”
Aloke, C., Adelusi, O. A., Onisuru, O. O., Iwuchukwu, E. A., & Achilonu, I. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70277 · Cited by 24
“Moreover, other reviews have provided summaries of the cardiovascular [19–21], renal [22], and safety data [23] related to the utilization of DPP-4is.”
The spectrum of diabetes in acute and chronic pancreatitis
Olesen, S. S., Toledo, F. G. S., & Hart, P. A. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000864 · Cited by 22
Chang, H., Hsieh, C.-F., Singh, S., Tang, W., Chiang, Y.-T., & Huang, W.-F. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3770 · Cited by 21
Fiorentino, T. V., Owston, M. A., ABRAHAMIAN, G. A., Rosa, S. L., Marando, A., Perego, C., Cairano, E. S. D., Finzi, G., Capella, C., Sessa, F., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.009 · Cited by 21
“The Food and Drug Administration and the European Medicines Evaluation Agency have recently reanalyzed all studies on GLP-1 receptor agonist and DPP-IV inhibitors and concluded that there is no significantly increased risk of either pancreatitis or dysplastic lesion/ pancreatic cancer in rodents, nonhuman primates, an…”
BackgroundLiraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
“conclusion regarding such a causal relationship.[50] In the preclinical development of liraglutide, an increased incidence of thyroid C-cell tumors was reported in rodent”
BackgroundTrujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
“Pancreatic Disease and Cancer Postmarketing data previously suggested a link between GLP-1 RAs and pancreatic disease, including pancreatic cancer.(60) However, only one case of pancreatitis was reported in the lixisenatide arm of GetGoal Duo-2,(32) whereas the other GetGoal trials did not report any cases of pancreat…”
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Chang, C., Lin, J., Chen, S., Lai, M., Chuang, L., & Chang, Y. (2016) · Medicine · doi:10.1097/md.0000000000002603 · Cited by 20
“Data from these studies did not identify exenatide-related pancreatic injury.(30) The major strength of this study is the enrollment of a huge nationwide cohort of diabetic patients.”
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Heimbürger, S. M. N., Brønden, A., Johansen, N. J., Dejgaard, T. F., Vilsbøll, T., & Knop, F. K. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571040 · Cited by 20
“These assessments concluded no causal association between incretin-based therapies and pancreatitis or pancreatic cancer to be evident [48].”
Backgroundde Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 21
“Up to date this effort provided no evidence of increased incretin-related pancreatic disease [64,70].”
BackgroundIncretin-mimetic therapies and pancreatic disease: a review of observational data
Suarez, E. A., Koro, C. E., Christian, J. B., Spector, A., de Araújo, A. B., & Abraham, S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.960515 · Cited by 21
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
On behalf of the KIND-LM study investigators, Tanaka, K., Saisho, Y., Manesso, E., Tanaka, M., Meguro, S., Irie, J., Sugiura, H., Kawai, T., Jinzaki, M., et al. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0331-5 · Cited by 20
“A pooled analysis of phase 3 studies and large-scale cohort analyses have shown no increase in the incidence of pancreatitis with incretin therapy [27–29], and currently no causal association between incretin therapy and pancreatitis has been confirmed [30].”
BackgroundPrato, S. D., & CHILTON, R. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13169 · Cited by 22
“The increased risk of pancreatitis reported in early observational studies have not been confirmed in a number of investigations and a meta-analysis,90,91 leading the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) to conclude that there is no final evidence for a certain increase in the risk…”
BackgroundInfluentialGLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
Crisci, I., Aragona, M., Politi, K. S., Daniele, G., & Prato, S. D. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0800-6 · Cited by 19
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
Woo, V. C. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12720 · Cited by 19
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
“Following comprehensive safety assessments, in 2014, the FDA and European Medicines Agency agreed that ‘assertions concerning a causal relationship between incretin therapies and pancreatitis or pancreatic cancer are inconsistent with the current data,’ but that ‘pancreatitis will continue to be considered a risk asso…”
BackgroundRengasamy, K. R. R., Slavětínská, L. P., Kulkarni, M. G., Stirk, W. A., & Staden, J. V. (2017) · Algal Research · doi:10.1016/j.algal.2017.05.008 · Cited by 18
Pozo, L., Bello, F. O., Suárez, A., Ochoa-Martinez, F. E., Mendez, Y. H., Chang, C., & Surani, S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.291 · Cited by 20
PAGE, L. C., & Freemark, M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00409-7 · Cited by 19
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 19
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
Funch, D. P., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Li, L., Norman, H. S., Major‐Pedersen, A., Bosch‐Traberg, H., Gydesen, H., & Dore, D. D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13739 · Cited by 17
“Both agencies called for more research in this area.(10,11) Thus, this post-marketing regulatory requirement supplements the growing body of studies utilizing real world data and methods to address concerns about confounding and bias in observational studies.”
BackgroundScholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“More recently, a meta-analysis of 41 randomized clinical studies with GLP-1 RAs showed no increase in the risk of pancreatitis with the use of GLP-1 RAs [73], and recent incretin pancreatic safety reviews by both the FDA and EMA found no evidence of a causal relationship [74].”
BackgroundYabe, D., Kuwata, H., Usui, R., Kurose, T., & Seino, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1045471 · Cited by 16
Dedov, I. I., Shestakova, M. V., As, A., Анциферов, М. Б., Galstyan, G. R., Mayorov, A. Y., Mkrtumyan, A. M., Petunina, N. A., & Sukhareva, O. Y. (2015) · Diabetes Mellitus · doi:10.14341/dm201515-23 · Cited by 18
Sitagliptin‐induced pancreatitis – a longer road than expected
Nelson, M., Bhandari, N., & Wener, J. (2014) · Clinical Case Reports · doi:10.1002/ccr3.83 · Cited by 15
“The FDA did not find an increased risk of pancreatitis in their review, and they considered the labeling already in place regarding reports of pancreatitis appropriate [16].”
BackgroundOral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 24
Naseralallah, L. M. A., & Aboujabal, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181074 · Cited by 18
“Pancreatitis and its biochemical markers Tirzepatide is an incretin-based therapy in which several case reports have raised the risk of acute pancreatitis, chronic pancreatitis, and pancreatic adenocarcinoma [55].”
BackgroundRole of GLP‐1 Receptor Agonists in Managing Cancer Therapy–Related Cardiac Dysfunction
Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040919 · Cited by 14
Scheen, A. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1041499 · Cited by 14
Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective)
Goriacko, P., & Veltri, K. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_10 · Cited by 15
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2
Al‐Horani, R. A., & Chedid, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221004151212 · Cited by 15
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Triplitt, C. L., & Solis‐Herrera, C. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607981 · Cited by 17
“Recent parallel assessments of the pancreatic safety of incretin-based therapies were conducted by the US Food and Drug Administration and European Medicines Agency using data from clinical trials, epidemiologic studies, and toxicology studies.(82) Based on the available evidence, it was concluded that proposed causal…”
Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation
Barnett, A. H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.971008 · Cited by 14
“Pancreatitis is, nevertheless, considered a potential risk associated with all incretinbased therapies [65], and prescribing information state to discontinue treatment if pancreatitis is suspected.”
BackgroundRaccah, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.007 · Cited by 15
Schwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 15
“However, a recently published assessment from the FDA and European Medicines Agency (EMA) reassures us that evidence is lacking regarding a causal relationship between GLP-1 therapy and pancreatitis or pancreatic cancer [152].”
BackgroundDIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Kristin, E. (2016) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci004802201606 · Cited by 18
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Optische Kontrolle der Insulinsekretion mit einem Inkretinschalter
Broichhagen, J., Podewin, T., Meyer‐Berg, H., von Ohlen, Y., Johnston, N. R., Jones, B. J., Bloom, S. R., Rutter, G. A., Hoffmann‐Röder, A., Hodson, D. J., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201506384 · Cited by 13
Albiglutide for the management of type 2 diabetes
Rendell, M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1419061 · Cited by 16
Meece, J. D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0491-1 · Cited by 16
Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.007 · Cited by 13
Current and emerging pharmacotherapies for obesity in Australia
HOCKING, S. L., Dear, A. E., & Cowley, M. A. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.07.002 · Cited by 14
Incretin-based therapy and pancreatic beta cells
Chon, S., Riveline, J., Blondeau, B., & Gautier, J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.05.003 · Cited by 14
“[88] Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al.”
BackgroundIncretin Physiology and Pharmacology in the Intensive Care Unit
Plummer, M. P., Hermanides, J., & Deane, A. M. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.011 · Cited by 12
Scheen, A. J. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30042-0 · Cited by 33
Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review
Pratley, R. E., Heller, S. R., & Miller, M. A. (2014) · Endocrine Practice · doi:10.4158/ep13192.ra · Cited by 13
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Soranna, D., Bosetti, C., Casula, M., Tragni, E., Catapano, A. L., Vecchia, C. L., Merlino, L. G., & Corrao, G. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.013 · Cited by 13
“Meta- and pooled-analyses of clinical trials reported no difference in the incidence rates of pancreatitis for sitagliptin use compared with use of placebo or other oral hypoglycaemic drugs [20–22].”
BackgroundUsborne, A. L., Byrd, R. A., Meehan, J., Blackbourne, J. L., Sullivan, J., Poitout‐Belissent, F., Préfontaine, A., Martin, J. A., & Vahle, J. L. (2015) · Toxicologic Pathology · doi:10.1177/0192623315596857 · Cited by 12
“2010; Ahmad and Swann 2008); however, extensive reviews of both preclinical animal and clinical human data by the FDA and European Medicines Agency (EMA) find these assertions to be inconsistent with their reviewed data (Egan et al. 2014).”
BackgroundInfluentialNassar, M., Abosheaishaa, H. M., Misra, A., Dandona, P., Ghanim, H., & Chaudhuri, A. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101613 · Cited by 11
Immunoengineering strategies using nanoparticles for obesity treatment
Mohaghegh, N., Balajam, N. Z., Hosseinpour, B., Buttles, C., Huang, Q., Huang, Y., Ahari, A. F., Farhadi, N., Davani, S., Khosravi, S., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907707 · Cited by 11
Pancreatic Safety of Newer Incretin-Based Therapies: Are the “-tides” Finally Turning?
Devaraj, S., & Maitra, A. (2014) · Diabetes · doi:10.2337/db14-0545 · Cited by 12
“A recent perspective of the pancreatic safety of incretin-based drugs (16) clearly documents data from the FDA and European Medicines Agency (EMA), including liraglutide therapy, for a duration of 52 weeks or more and provides no compelling evidence for increased risk of pancreatitis or pancreatic cancers (9,17).”
BackgroundVahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T. E., Pienkowski, T. P., Rosol, T. J., Snyder, P. W., & Klöppel, G. (2015) · Toxicologic Pathology · doi:10.1177/0192623315588999 · Cited by 11
“2013) in ZDF rats did not demonstrate definitive drug-related adverse effects on exocrine pancreas histology or proliferation (Egan et al. 2014).”
BackgroundHong, J., Buse, J. B., Funk, M. J., Pate, V., & Stürmer, T. (2018) · Diabetes Care · doi:10.2337/dc17-2212 · Cited by 11
“an increased risk of acute pancreatitis (4,5).”
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Formiga, F., Gómez‐Huelgas, R., & Rodríguez‐Mañas, L. (2015) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2015.04.002 · Cited by 18
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“Currently, the US FDA and the European Medicines Agency have concluded that there is no direct possibility with GLP1-RAs [116].”
Background
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.